|1.||Saito, Yasushi: 11 articles (11/2011 - 01/2002)|
|2.||Yamagishi, Masakazu: 10 articles (06/2015 - 12/2006)|
|3.||Daida, Hiroyuki: 10 articles (01/2013 - 06/2004)|
|4.||Hounslow, Neil: 9 articles (12/2015 - 05/2010)|
|5.||Hiro, Takafumi: 9 articles (03/2015 - 12/2006)|
|6.||Matsuzaki, Masunori: 9 articles (01/2013 - 11/2006)|
|7.||Ozaki, Yukio: 9 articles (01/2013 - 12/2006)|
|8.||Miyauchi, Katsumi: 9 articles (01/2013 - 06/2004)|
|9.||Teramoto, Tamio: 8 articles (08/2015 - 01/2002)|
|10.||Kimura, Takeshi: 8 articles (01/2013 - 12/2006)|
04/10/2012 - "To evaluate the safety and efficacy of pitavastatin in patients with hypercholesterolemia in China under conditions of extensive usage. "
04/10/2012 - "[Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study]."
03/01/2010 - "Articles included were those pertaining to the pharmacology and pharmacokinetic properties of pitavastatin, in addition to original research evaluating the clinical efficacy of pitavastatin for hypercholesterolemia. "
04/01/2008 - "One year of pitavastatin treatment improved not only carotid arterial stiffness but also regional LV systolic and diastolic function in patients with hypercholesterolemia and preserved LVEF. "
11/01/2011 - "Overall, results from the LIVES study show that pitavastatin is well tolerated and effectively modifies atherogenic lipid profiles, thereby reducing CV and cerebrovascular risk in Japanese patients with hypercholesterolemia. "
09/01/2014 - "Pitavastatin is an effective therapeutic alternative for patients with dyslipidemia."
09/01/2014 - "The following data were collected in each case: Morisky-Green test and TSQM-9 for patients older than 18 years old, with dyslipidemia treated with pitavastatin in the last 12 weeks. "
09/01/2014 - "[Effectivity and satisfaction with the treatment for dyslipidemia with pitavastatin. "
12/01/2013 - "Searching the place of pitavastatin in the current treatment of patients with dyslipidemia."
01/01/2013 - "A total of 30 patients with dyslipidemia were treated with 2 mg of pitavastatin for four weeks. "
08/01/2015 - "To assess the safety and efficacy of pitavastatin in children and adolescents with hyperlipidemia. "
03/01/2010 - "To investigate the SLCO1B1 388A>G and 521T>C polymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin. "
08/01/2015 - "A total of 106 children and adolescents with hyperlipidemia, ages 6 to 17 years, were enrolled in a 12-week randomized, double-blind, placebo-controlled study and randomly assigned to pitavastatin 1 mg, 2 mg, 4 mg, or placebo. "
01/01/2015 - "Until data become available distinguishing pitavastatin from the other available options, its ultimate role in the hyperlipidemia treatment armamentarium remains unclear. "
01/01/2013 - "Pitavastatin improves postprandial oxidative stress along with hyperlipidemia. "
01/01/2015 - "Pitavastatin not only improved the atherosis as measured by IMT and cIBS values but also attenuated inflammation of plaques as measured by max SUV at the same site. "
10/01/2009 - "Pitavastatin improved serum lipid profiles and reduced serum hsCRP levels in type 2 diabetic patients with relatively low inflammation. "
01/01/2015 - "Our study provides in vivo evidence that pitavastatin reduces inflammation within atherosclerotic lesions in CRD mice."
01/01/2015 - "Nanoparticle-mediated targeting of pitavastatin induced cardioprotection from IR injury by activation of PI3K/Akt pathway and inhibition of inflammation and cardiomyocyte death in this model. "
01/01/2015 - "Pitavastatin-NP induced phosphorylation of Akt and GSK3β, and inhibited inflammation and cardiomyocyte apoptosis in the IR myocardium. "
|5.||Diabetic Nephropathies (Diabetic Nephropathy)
11/01/2005 - "Urinary l-FABP levels appear to be associated with the progression of diabetic nephropathy, and pitavastatin may be effective in ameliorating tubulointerstitial damage in early diabetic nephropathy."
08/01/2007 - "Our study demonstrates that pitavastatin ameliorates diabetic nephropathy in db/db mice by minimizing oxidative stress by downregulating NOX4 expression. "
11/01/2005 - "The aim of this study was to determine whether urinary l-FABP levels are altered at various stages of diabetic nephropathy and whether pitavastatin affects urinary l-FABP levels in early diabetic nephropathy. "
07/01/2012 - "Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy."
11/01/2005 - "Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy."
|5.||Coenzyme A (CoA)
|10.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)